Evonik's Board Will Share a Room With BASF, Not a Price

Evonik's refusal to negotiate with BASF has left two companies staring at the same number and seeing entirely different things. BASF looks at its €24.00-per-share offer and sees a 39% premium to the undisturbed closing price. Evonik's management board looks at the same figure and sees a number it is not prepared to discuss.

That gap widened on Wednesday, when BASF chief executive Markus Kamieth reaffirmed his interest in Evonik to reporters while insisting the group would not pay "excessive prices" for the business. The two statements sit awkwardly together, and they frame the standoff precisely: BASF is willing to buy, but only at its own valuation, and Evonik has declined to put a counter-view on the table.

A premium is not a valuation

BASF's case rests on the premium. By its own account, €24.00 represents roughly 39% above Evonik's unaffected closing price, and the bidder has said it cannot understand why that is not enough to open talks. What the premium does not settle is the value Evonik's board attaches to the company — and that is exactly where the two sides part ways. Reuters reported before the official statement, citing the Financial Times, that Evonik considered the offer too low; the subsequent company release confirmed the rejection of negotiations.

Evonik did agree to one thing: a confidential exchange of information, which the board explicitly described as purely informational. For shareholders, that distinction carries real weight. Consent to talk is not consent to negotiate a voluntary public takeover offer, and it should not be read as agreement on a shared process.

Should investors sell immediately? Or is it worth buying Evonik?

The sequence behind the standoff is now clear. BASF first signalled its interest in a letter dated 22 October, and Kamieth's public remarks on Wednesday doubled down on that interest without loosening the price discipline attached to it. Evonik, for its part, has refused to enter negotiations at all. The offer is therefore a concrete reference point, but not a company value both sides have accepted.

What the share price does and does not say

Wednesday's close of €21.06 sat below the named offer price, a gap that reflects hope rather than entitlement. The bid is a possible transaction size, not a guaranteed floor under the stock. Whether the two sides can even find common ground is the open question, and the willingness to exchange information should be treated as neither a yes nor a definitive no.

BASF's accompanying commitments on jobs and sites could yet become talking points. Whether they would move Evonik's position cannot be inferred from the rejection, and a higher price is neither required nor promised. A constructive outcome would not have to rest on a fresh financial concession; it could begin with the two sides simply narrowing their positions. What would actually matter is an explicit readiness to negotiate terms — a change of stance, not another round of confidential contact.

Against that sits the counterweight: Evonik's refusal combined with BASF's declared price ceiling. Interest and willingness to pay are plainly not unlimited. Should the information exchange fail to produce movement, the takeover prospect could lose weight, and investors should not assume every rejection automatically summons a sweeter bid. Kamieth's remark argues against that certainty without announcing any withdrawal.

Syneqt adds a second strategic question

Even a deal would not resolve everything. Evonik subsidiary Syneqt insisted on Tuesday, according to Reuters, on remaining independent — including under BASF. Evonik had earmarked the unit for sale and had previously planned to start the divestment process next year, so the group's future shape would remain under discussion alongside the takeover question itself.

Evonik at a turning point? This analysis reveals what investors need to know now.

November 3 shifts the focus back to operations

The next fixed date on the calendar is 3 November 2026, when Evonik publishes its quarterly statement for the third quarter of 2026. No decision on the takeover conflict is scheduled for that day. What the report can do is give investors a fresh basis for valuing Evonik on its own merits, separate from any possible buyer.

That leaves two tracks to keep apart: the operating assessment of the company and the odds of a transaction. As long as BASF maintains its interest and Evonik permits the informational exchange, a later rapprochement stays possible; if the refusal to negotiate holds, the crucial step toward a jointly agreed deal never happens. A withdrawal by BASF would be an additional negative scenario, but no such move has been announced. For the deal track, the next reaffirmation of interest will not be the signal that counts — a visible shift from information to negotiation would be.

Ad

Evonik Stock: New Analysis - 31 October

Fresh Evonik information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Evonik analysis...